Table 2.

Treatment and final outcomes of eyes with exudation and/or fibrovascular proliferation.

Patient	Treatment	Duration of follow-up (years)	Final Visual Acuity		Exudative and Anatomical Status
			Affected eye	Fellow eye	Affected eye	Fellow eye
1	IVB x4, PPV	6.7	20/250	NLP	Stable, no exudation	Phthisis
2	IVB x5,	4.7	NLP	NLP	Phthisis	Phthisis
3	IVB x3, PPV	5.3	NLP	HM	Phthisis	Retinal folds
4	None	1.0	20/200	20/200	Stable with yellow exudates	Retinal dragging
5	Cryotherapy, IVB x3	6.7	20/50	Enucleated	Stable with no exudation	Enucleated

IVB – Intravitreal bevacizumab, NLP - No light perception